Introduction {#sec1-1}
============

Day by day the medicines we know are becoming less effective because of the ability of microorganisms to resist the effects of the medications that were once used to kill them \[[Table 1](#T1){ref-type="table"}\]. This ability of the microorganisms is known as antimicrobial resistance (AMR) \[[Graph 1](#F1){ref-type="fig"}\].\[[@ref1]\] Because of this, the medications have become ineffective and the microorganisms persist for a longer time in the body, and the risk of the spread of the infections and diseases increases and threatens our ability to cure even the common infections. This may result in prolonged illness, disability, and even death \[[Graph 2](#F2){ref-type="fig"}\]. And without effective antimicrobials, medical procedures and major surgeries also become very risky. In addition, AMR increases the cost of healthcare as stays in the hospitals will be longer and more intensive care will be required. The global health threats of AMR rose to a crescendo and is putting the gains of the Millennium Development Goals and Sustainable Development Goals at peril.\[[@ref2]\]

###### 

Some of the recent occurrences of antimicrobial-resistant microbes and the antimicrobials they are resistant to

  Microorganism                                                                          Antimicrobial Resistance toward                                                                                                    Year
  -------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------
  *Staphylococcus*                                                                       Penicillin                                                                                                                         1940
  *Shigella*                                                                             Tetracycline                                                                                                                       1959
  *Staphylococcus*                                                                       Methicillin                                                                                                                        1962
  *Pneumococcus*                                                                         Penicillin                                                                                                                         1965
  *Streptococcus*                                                                        Erythromycin                                                                                                                       1968
  *Enterococcus*                                                                         Gentamicin                                                                                                                         1979
  *Enterobacteriaceae*                                                                   Ceftazidime                                                                                                                        1987
  *Enterococcus*                                                                         Vancomycin                                                                                                                         1988
  *Pneumococcus*                                                                         Levofloxacin                                                                                                                       1996
  *Enterobacteriaceae*                                                                   Imipenem                                                                                                                           1998
  Extensively drug-resistant tuberculosis (XDR-TB)                                       Isoniazid, Rifampicin, Fluoroquinolones, and many more of the three second-line injectable drugs.\[[@ref3]\]                       2000\[[@ref1]\]
  *Staphylococcus*                                                                       Linezolid                                                                                                                          2001
  *Staphylococcus*                                                                       Vancomycin                                                                                                                         2002
  Pan-Drug Resistant (PDR)- Acinetobactor                                                All Cephalosporins and inhibitor combinations, Fluroquinolones, Aminoglycosides, Carbapenems, Polymyxins.\[[@ref4]\]               2004/05\[[@ref1]\]
  PDR-Pseudomonas                                                                        Penicillins, Cephalosporins, Carbapenems, Monobactams, Quinolones, Aminoglycosides, and Polymyxins.\[[@ref5]\]                     2004/05
  *Escherichia coli*                                                                     Third-generation cephalosporin-resistant                                                                                           2007\[[@ref6]\]
  *Neisseria gonorrhoeae*                                                                Ceftriaxone                                                                                                                        2009
  *Klebseilla pneumoniae*                                                                Carbapenem, Colistin                                                                                                               2009\[[@ref7]\]
  *Staphylococcus*                                                                       Ceftraroline                                                                                                                       2011\[[@ref1]\]
  *Neisseria gonorrhoeae*                                                                Azithromycin                                                                                                                       2011\[[@ref8]\]
  Multi-Drug Resistant Tuberculosis (MDR-TB)                                             Rifamycin, Isoniazid, Pyrazinamide                                                                                                 2012\[[@ref9]\]
  *Salmonella paratyphi*                                                                 Ampicillin, Cefotaxime, Ceftazidime, Ceftriaxone, Nalidixic acid, Aztreonam, Trimethoprim/sulfamethoxazole                         2013\[[@ref10]\]
  *Escherichia coli*                                                                     Carbapenem                                                                                                                         2015\[[@ref6]\]
  *Enterococcus faecalis*                                                                Vancomycin                                                                                                                         2015\[[@ref6]\]
  *Plasmodium falciparum*                                                                Artemisinin-based combination therapies (ACTs)                                                                                     2016\[[@ref11]\]
  *Salmonella typhi*                                                                     Fluoroquinolones, Ampicillin, Chloramphenicol, Trimethoprim-sulfamethoxazole, Third-generation cephalosporins                      2016\[[@ref12]\]
  New Delhi metallo-beta-lactamase (NDM) type carbapenemase-producing organisms (CPOs)   β-lactam antibiotics\[[@ref13]\]                                                                                                   2017\[[@ref14]\]
  *Clostridium difficile*                                                                Aminoglycosides, Lincomycin, Tetracyclines, Erythromycin, Clindamycin, Penicillins, Cephalosporins, Fluoroquinolones\[[@ref15]\]   2017\[[@ref14]\]

![The number of microorganisms becoming antibiotic resistant is on a rise](JFMPC-9-2192-g001){#F1}

![The approximate number of infections and deaths caused by certain antibiotic-resistant microorganisms](JFMPC-9-2192-g002){#F2}

Centers for Disease Control and Prevention (CDC), USA categorized antibiotic-resistant bacteria into three levels \[[Table 2](#T2){ref-type="table"}\]:

###### 

Categorization of antibiotic-resistant bacteria into three levels by Center for Disease Control and Prevention (CDC), USA.\[[@ref16]\]

  Category                                               Microorganisms                                                                                                         Antimicrobial Resistance toward
  ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  *Concerning Threats*                                   *Vancomycin-resistant Staphylococcus aureus*                                                                           Vancomycin
  *Erythromycin-resistant Group A Streptococcus*         Erythromycin                                                                                                           
  *Clindamycin-resistant Group B Streptococcus*          Clindamycin                                                                                                            
  *Serious Threats*                                      *Multidrug-resistant Acinetobacter*                                                                                    All cephalosporins and inhibitor combinations, Fluoroquinolones, Aminoglycosides\[[@ref4]\]
  *Drug-resistant Campylobacter*                         Fluoroquinolones\[[@ref17]\]                                                                                           
  *Fluconazole-resistant Candida*                        Fluconazole                                                                                                            
  *Vancomycin-resistant Enterococci (VRE)*               Vancomycin                                                                                                             
  *Multidrug-resistant Pseudomonas aeruginosa*           Imipenem, Ceftazidime, Ciprofloxacin, Tobramycin\[[@ref18]\]                                                           
  *Drug-resistant Salmonella typhimurium*                Ampicillin, Trimethoprim-sulfamethoxazole, Chloramphenicol, Fluoroquinolones, Ceftriaxone, Azithromycin\[[@ref19]\]    
  *Drug-resistant Shigella*                              Sulphonamides, Tetracycline, Chloramphenicol, Ampicillin, Co-Trimoxazole\[[@ref20]\]                                   
  *Methicillin-resistant Staphylococcus aureus (MRSA)*   Methicillin                                                                                                            
  *Drug-resistant Streptococcus pneumonia*               Penicillin, Erythromycin, Trimethoprim-sulfamethoxazole, Tetracycline, Chloramphenicol, Fluoroquinolones\[[@ref21]\]   
  *Urgent Threats*                                       *Clostridium difficile*                                                                                                Aminoglycosides, Lincomycin, Tetracyclines, Erythromycin, Clindamycin, Penicillins, Cephalosporins, Fluoroquinolones\[[@ref15]\]
  *Carbapenem-resistant Enterobacteriaceae (CRE)*        Carbapenem                                                                                                             
  *Drug-resistant Neisseria gonorrhoeae*\[[@ref16]\]     Sulfonamides, Penicillins, Cephalosporins, Tetracyclines, Macrolides, Fluoroquinolones\[[@ref22]\]                     

Concerning: Bacteria belonging to this classification have the threat of antibiotic resistance as "low." There may or may not be multiple options of therapeutics for the infections of bacterial resistance. These bacteria usually cause severe illness. To monitor these categorical threats, outbreak responses or rapid incidents are required.

Serious: These are significant threats. For various reasons like low or declining domestic incidences or reasonable availability of therapeutic agents, they may not be considered urgent but on a long run, the threats will worsen to turn urgent due to the lack of prevention activities and public health monitoring.

Urgent: The antibiotic resistance threats belonging to this category result in high consequences. Significant risks across various criteria have been attached to these bacteria. These might have the potential to be widespread due to lack of public attention that may identify infections and limit transmission.\[[@ref16]\]

Factors that Cause AMR {#sec1-2}
======================

Increase in AMR is linked with the amount of the antibiotic prescribed, number of doses missed, and inappropriate and unnecessary prescribing of antibiotics which happen maybe because sometimes patients insist physicians for antibiotics and the physicians prescribe them as they do not have time to explain why they are not needed\[[@ref23][@ref24]\]Lower antibiotic concentrations\[[@ref25]\] and longer duration of treatment\[[@ref26]\] contribute to the increase of AMRUnderlying diseases in the healthcare setup such as mechanical ventilation and poor hygiene by hospital staff have also been associated with the spread of resistant organisms\[[@ref27]\]:AMR raise the crescendo when counterfeit medications with subtherapeutic concentrations of antibiotics are used\[[@ref28]\]Some of the pharmaceutical companies release large amounts of antibiotics in the form of waste due to inappropriate wastewater treatment which eventually increases AMR\[[@ref29]\]Antibacterial components\[[@ref30]\] and antiseptics\[[@ref31]\] may also be contributing to AMRInappropriate use of antibiotics in animal husbandries is also found to be an underlying contributor to the emergence and spread of antibiotic-resistant microbes\[[@ref32]\]Resistance toward antibiotics sometimes is also natural. These genes that gain resistance are called as environmental resistomes. These genes may be transferrable from non-pathogenic to pathogenic microbomes which may lead to antibiotic resistance\[[@ref33]\]It has been found that heavy metals and other pollutants may also be contributing toward this global public health hazard.\[[@ref34]\]

Global Overview of Antimicrobial Resistance {#sec1-3}
===========================================

In U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result every year \[[Table 3](#T3){ref-type="table"}\].\[[@ref35]\] In the E.U., 33000 deaths due to antibiotic-resistant bacteria are reported every year.\[[@ref6]\]

###### 

Deaths attributable to AMR by 2050

  Continent       Number of deaths
  --------------- ---------------------
  Asia            4,730,000
  Africa          4,150,000
  Europe          390,000
  North America   317,000
  Oceania         22,000
  South America   392,000\[[@ref36]\]

To combat AMR, new drugs are being made or combinations of already existing drugs are being used \[[Table 4](#T4){ref-type="table"}\].\[[@ref37]\]

###### 

Drugs that work and do not work on certain antibiotic-resistant microorganisms

  Microorganism                                     Antibiotics that do not work                                                                               Antibiotics that work
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  MRSA                                              Β-lactam antibiotics                                                                                       Vancomycin, Teicoplanin, Daptomycin, Linezolid\[[@ref38]\]
  VRE                                               Vancomycin                                                                                                 Linezolid, Dalfopristin, Daptomycin, Tigecycline, Telavancin\[[@ref39]\]
  *Streptococcus pneumoniae*                        Penicillin, Erythromycin, Trimethoprim-sulfamethoxazole\[[@ref21]\]                                        PCV7, PCV13\[[@ref40]\]
  XDR-TB                                            Isoniazid, Rifampicin, Fluoroquinolones, and any of the three second-line injectable drugs                 Fewer treatment options are available, and the drugs available are much less effective\[[@ref3]\]
  CRE                                               All or nearly all available antibiotics                                                                    Aminoglycosides, Polymyxins, Tigecycline, Fosfomycin, and Temocillin have been used with some success\[[@ref41]\]
  *Pseudomonas aeruginosa*                          Aminoglycosides, Imipenem, Ceftazidime, Ciprofloxacin, Tobramycin                                          Polymyxins, β-lactam antibiotics, Carbapenems\[[@ref18]\]
  ESBL-producing Enterobacteriaceae                 Penicillins, First-, second-, and third-generation cephalosporins, and Aztreonam                           Carbapenem, Clavulanic acid\[[@ref42]\]
  *Cephalosporin-resistant Neisseria gonorrhoeae*   Cephalosporin, Fluoroquinolones, Tetracyclines, Penicillins, Macrolides                                    Extended Spectrum Cephalosporins (ESCs like- Cefixime, Ceftriaxone), Spectinomycin, Azithromycin.\[[@ref22]\]
  MDR-*Acinetobacter baumannii*                     All penicillins and cephalosporins (including inhibitor combinations), Fluoroquinolones, Aminoglycosides   Colistin, Tigecycline\[[@ref4]\]
  *Non-Typhoidal Salmonella*                        Ampicillin, Chloramphenicol, Co-trimoxazole, Sulphonamides, Tetracycline                                   Ciprofloxacin, Cefotaxime, Ceftriaxone, Cefoperazone, Aztreonam, Azithromycin\[[@ref19]\]

Indian Scenario {#sec1-4}
===============

India also carries the burden of AMR, including the highest number of MDR-TB.\[[@ref43]\] Antimicrobial-resistant microbes have also been found in various animals other than humans like cows, buffaloes, fishes, shrimps, shellfishes, crabs, etc., Even natural resources like water bodies are not safe as antimicrobial-resistant bacteria and their genes have also been found in some of the water sources of India.\[[@ref44]\]

In India, resistance toward fluoroquinolones, carbapenem, and colistin is found to be high among Gram-negative and Gram-positive bacteria \[[Table 5](#T5){ref-type="table"}\]. High resistance toward even the newer antimicrobials like carbapenems and faropenem has been reported.\[[@ref45]\] Studies have reported high resistance toward fluoroquinolones and cephalosporinsins (third generation) pathogens such as *Salmonella typhi, Shigella, Pseudomonas*, and *Acinetobacter*.

###### 

AMR microorganisms found in India and the antimicrobials they are resistant to

  AMR Microorganisms                                    Antibiotic Resistance Toward
  ----------------------------------------------------- ---------------------------------------------------------------------------------
  *Escherichia coli*                                    Third-generation Cephalosporins,
  Fluoroquinolones, Carbapenem, Ampicillin,             
  Naladixic acid, Co-trimoxazole.\[[@ref49][@ref50]\]   
  *Salmonella species*                                  Ciprofloxacin, Gentamicin, Tetracycline,
  Ceftriaxone, Co-trimoxazole, Ampicillin,              
  Nalidixic acid, Fluoroquinolones, Third               
  Generation Cephalosporins. \[[@ref46][@ref55]\]       
  *Vibrio cholera*                                      Ampicillin, Tetracycline, Chloramphenicol,
  Ceftazidime.\[[@ref44][@ref56]\]                      
  *Vibrio parahaemolyticus*                             Ampicillin, Chloramphenicol, Ceftazidime.\[[@ref56]\]
  *Staphylococcus aureus*                               Vancomycin, Methicillin.\[[@ref47][@ref52]\]
  *Shigella species*                                    Ceftriaxone, Co-trimoxazole, Third Generation Cephalosporins, Fluoroquinolones,
  Azithromycin, Chloramphenicol, Ampicillin,            
  Nalidixic acid\[[@ref20]\]                            
  *Enterococcus faecium*                                Vancomycin\[[@ref46]\]
  *Klebsiella pneumoniae*                               Carbapenem, Fluoroquinolones, Third-generation Cephalosporins.\[[@ref50]\]
  *Acinetobacter baumannii*                             Fluoroquinolones, Third Generation
  Cephalosporins.\[[@ref46]\]                           
  *Pseudomonas aeruginosa*\[[@ref44]\]                  Fluoroquinolones, Third Generation
  Cephalosporins.\[[@ref46]\]                           

It has been estimated that more than 50,000 newborns will die from sepsis due to pathogens being resistant to first-line antimicrobials. It is thought that neonates and elderly will be affected worse. It is estimated that more than two million deaths will occur in India due to AMR by the year 2050.\[[@ref46]\] About 29% of isolated *S. aureus* in 2008 were methicillin resistant which by 2014, has reached 47%.\[[@ref47]\] In addition, since 2011 MDR-yeast has also been reported in India. In another study conducted in 2015, researchers found AMR among *Enterobacter cloacae* and *Morganella morganii* in people residing in Burail, a semi-urban community in Chandigarh.\[[@ref48]\] Around 17% to 75% of the *Vibrio cholera*e have been found to be resistant toward tetracycline.\[[@ref44]\] Between 2004 and 2007, *E. coli* samples showed 73%, 59%, and 75% of rate of resistance to naladixic acid, co-trimoxazole, and ampicillin, respectively.\[[@ref49]\] Also from 2008 to 2013, resistance of E. coli to cephalosporins (third generation) has increased from 70% to 83%, whereas resistance of fluoroquinolone has increased from 78% to 85%, and carbapenems resistance increased from 10% to 13%.\[[@ref50]\]

From 2008 to 2014, the rate of resistance toward fluoroquinolones in *S.typhi* was found to be increased from 8% to 28%. In addition, *S. typhi* are becoming nalidixic acid resistant as use of other quinolones is increasing. But in 2014, the rate of *S. typhi* resistance toward ampicillin and co trimoxazole was found to be decreasing. 11% of the *Enterococcus faecium* isolates were found to be vancomycin resistant.\[[@ref46]\] From 2002 to 2009, *K. pneumonia* associated carbapenem resistance has significantly increased from 2% to 52%. In addition, the fluoroquinolone resistance had increased from 57% to 73%. However, the resistance rate of *K*. pneumoniae isolates toward cephalosporins (third generation) had decreased from 90% to 80%.\[[@ref50]\]

A study found that 48% of the bacteria (Gram-negative) in the milk of buffalo and cow in West Bengal were detected to be extended spectrum beta lactamase (ESBL)producers and in Gujarat, 47.5% were oxytetracycline resistant.\[[@ref51]\] Also among the bacteria (Gram-positive) isolated from the same milk samples, 2.4% of *S. aureus* in West Bengal were vancomycin resistant,\[[@ref52]\] while in Karnataka, 21.4% *S. aureus* were MRSA.\[[@ref53]\] In Maharashtra, 48% of the Enterobacteriaceae isolated from the fish gut of Tilapia were producing ESBL.\[[@ref54]\] The rate of ESBL-producing Enterobacteriaceae in Odisha, Madhya Pradesh, and Punjab was found to be 9.4%, 33.5%, and 87%, respectively.\[[@ref55]\] In Kerala, *Vibrio cholera* and *Vibrio parahaemolyticus* found in shrimps, crabs, and shellfish were found to be totally resistant to ampicillin, ceftazidime resistance also ranged from 67% to 96% but were found to be susceptible to chloramphenicol.\[[@ref56]\] Another study showed the presence of MDR *Salmonella* species in Bihar and West Bengal being resistant to ciprofloxacin, gentamicin, and tetracycline.\[[@ref55]\]

Antimicrobial-resistant microbes have been found in water sources too. All of the samples of *E. coli* isolated from Kaveri in Karnataka were found to be resistant toward cephalosporins (third generation).\[[@ref57]\] The ground and surface water used for drinking along with recreational purposes in central India, Kashmir, Sikkim, and Hyderabad have been reported with 17%, 7%, 50%, and 100% rate of third-generation resistant *E. coli*, respectively.\[[@ref57][@ref58][@ref59][@ref60]\] The rate of cephalosporin (third generation) resistant *E. coli* in domestic water alone, waste along with hospital effluent, and hospital effluent alone was found to be 25%, 70%, and 95%, respectively.\[[@ref61]\] The ESBL producers were 17.4% among bacteria (Gram-negative) isolated from Yamuna and Ganga.\[[@ref62]\]

Measures Taken to Overcome AMR {#sec1-5}
==============================

Some of the approaches for combating AMR are:

Educating people about AMR.Educating people about the rational use of antimicrobials.Control of substandard and counterfeit antimicrobials.Inducements such as developing new vaccines and drugs.Usage of alcohol-based hand cleansers for hands.\[[@ref63]\]72 h after the symptoms resolve, antibiotics can be safely stopped.\[[@ref64]\]Usage of antibiotics with short course along with regular reevaluation with the doctor is necessary. The course must be stopped if no signs of clinical infection are seen as most of the time individuals do not complete the full course.Increasing awareness among the nurses and other health care providers is necessary as they are in direct contact with the patients and eventually being responsible for infection spread or control of AMR.\[[@ref65]\]The standards of drug advertising and promotions should be followed by pharmaceutical companies. Moreover, action toward pharmaceutical companies that encourage inappropriate use of antimicrobials should be taken.\[[@ref66]\]Minimized antimicrobial usage in animals, improved sanitization along with the regulated provision of probiotics or supplements in vaccination and feed to control common animal diseases need to be administered.\[[@ref67]\]Collective national and international academic networks are necessary to identify new categories of antibiotics along with diagnostic technologies.Providing incentives for the development of new antimicrobials to pharmaceutical companies.\[[@ref66]\]

India {#sec1-6}
=====

In 2013, surveillance networks of AMR were started by the Indian Council of Medical Research and in 2014, the National Centre for Disease Control also started an AMR surveillance network to know the approximate extent of AMR. In 2015, these two organizations along with CDC started assessing the already existing IPC practices in India to formulate new guidelines for preventing hospital-acquired infections.\[[@ref68]\] The National Health Policy, 2017 calls for a rapid standardization of guidelines soliciting antibiotic use and limiting the use of antibiotics. In addition, OTC (over the counter) medications, banning or restricting the use of antibiotics as growth promoters in animal livestock, and pharmacovigilance including prescription audits inclusive of antibiotic usage in the hospital and community should be taken care of.\[[@ref69]\] Other policies that were created to deal with AMR are as follows.

National Antimicrobial Resistance Policy, India {#sec1-7}
===============================================

In 2011, national policy on AMR has been introduced. The objective of this policy is to increase awareness in the emergence of AMR and the factors influencing it. In addition, to establish programs such as antimicrobial rationalized usage and to provide incentives to develop new effective antimicrobial drugs, this policy came into act. This policy concentrates on three categories such as sentinel surveillance, point prevalence, and comprehensive surveillance. Some of the action plans included in the policy are as given below:\[[@ref70]\]

To establish surveillance system of AMRPrevention of infections along with respective control measuresTo increase awareness of rational antimicrobial use in all stakeholders.

National Action Plan on Antimicrobial Resistance (NAP-AMR) {#sec1-8}
==========================================================

The objective of NAP-AMR is to combat AMR and contribute to tackle this global health threat. This policy will help establish and strengthen governance mechanisms and volume of stakeholders to decrease the aftermath of AMR in India. The extent of NAP-AMR primarily emphasizes on resistance in bacteria.

The objectives of the NAP-AMR are:

To define the strategic priorities, key actions, outputs, responsibilities, and indicative timeline and budget to slow the emergence of AMR in India and strengthen the organizational and management structures to ensure intra- and inter-sectoral coordination with a One Health approach;To combat AMR in India through better understanding and awareness of AMR, strengthened surveillance, prevention of emergence and spread of resistant bacteria through infection prevention and control, optimized use of antibiotics in all sectors, and enhanced investments for AMR activities, research, and innovations; andTo enable monitoring and evaluation (M and E) of the NAP-AMR implementation based on the M and E framework.

The NAP-AMR has outlined six strategic priorities to tackle this public health challenge and these are to be implemented over 2017--2021. The first 5 strategic priorities of NAP-AMR are aligned with the Global Action Plan on AMR and the sixth strategic priority highlights India\'s role in the containment of AMR at the international level and at subnational/state level to ensure action at the ground level. The focus areas of the six strategic priorities of NAP-AMR are:

Improve awareness and understanding of AMR through i) effective communication and IEC resources to raise awareness among all stakeholders, including policymakers, general public, and farmers, and ii) education and training to improve the knowledge and behavior of professionals.Strengthen knowledge and evidence through surveillance by strengthening laboratories for evidence-informed policy-making in human, animal, food, and environment sectors. And by surveillance of AMR for evidence-informed policy-making in human, animal/food, and environment sectors.Reduce the incidence of infection through effective infection prevention and control in- i) Healthcare to reduce the burden of infection, ii) Animal health/food to reduce the spread of AMR and antimicrobials through animals and food and, iii) Community and community environment to reduce the spread of AMR and antimicrobials in the community and environment.Optimize the use of antimicrobial agents in health, animals, and food with the help of i) Regulations, access, and surveillance of antimicrobial use to ensure rational use without affecting access to antimicrobials, ii) Antimicrobial stewardship in healthcare to optimize the use of antimicrobials in humans, and iii) Animal health, agriculture to optimize the use of antimicrobials in animal and food sectors.Promote investments for AMR activities, research, and innovations by i) New medicines and diagnostics to ensure availability of effective diagnostics and drugs to treat infections, ii) Innovations to develop alternative approaches to manage infectious diseases, and iii) Financing to ensure sustainable resources for containment of AMR.Strengthen India\'s leadership on AMR with i) International collaborations to ensure India\'s contributions toward global efforts to contain AMR, ii) National collaborations to facilitate collaborations among vertical disease control programs and national stakeholders, and iii) State level collaborations to ensure action at the ground level against AMR.\[[@ref71]\]

Conclusion {#sec1-9}
==========

One of the most important statistics in the public health sector is that of AMR. The statistical overview of the drug-resistant microbes helps in enhancing people\'s knowledge along with helping with discovering new antimicrobials. Different policies give broad guidelines on how to combat the microbes from developing resistance. As mentioned in the review, microbes belonging to different generations which are classified on the basis of bacterial strains of a genus developing resistance are increased in both global and Indian scenario. Hence, to provide insight, this review holds great importance to the respective statistics.

Financial support and sponsorship {#sec2-1}
---------------------------------

Nil.

Conflicts of interest {#sec2-2}
---------------------

There are no conflicts of interest.
